- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
* IN BRIEF * 08 May 2019 By * Sarah Crunkhorn * Sarah Crunkhorn Immune checkpoint inhibitors (CPIs) and interleukin-2 (IL-2) have demonstrated clinical efficacy in cancer, but can cause
severe off-target adverse events. Ishihara et al. exploit the leakiness of the tumour vasculature and the high presence of collagen in the tumour stroma to target CPI and IL-2 directly to
the tumour, through the respective conjugation or fusion to the collagen binding domain (CBD) of the blood protein von Willebrand factor. In mouse models, the CBD-modified agents accumulated
in the tumour, increased tumour-infiltrating CD8+ T cells and exerted greater suppression of tumour growth compared with their unmodified forms, without toxicity. ACCESS OPTIONS Access
Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and
online access $209.00 per year only $17.42 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during
checkout ADDITIONAL ACCESS OPTIONS: _Nature Reviews Drug Discovery_ 18, 420 (2019) _doi: https://doi.org/10.1038/d41573-019-00081-0_ REFERENCES
